Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193388
Status:
COMPLETED
Last Update Posted:
2010-07-28
First Post:
2005-09-12
Brief Title:
Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this phase II trial we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer
Detailed Description:
Upon determination of eligibility all patients will be receive
Topotecan
Topotecan
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 104864664 | None | None | None |